Search Results

Your search for VIVUS, Inc. in News Releases returned 4 results

News Releases

• Apr 30, 2013, 09:30 ET

  The Zacks Analyst Blog Highlights: Merck, GlaxoSmithKline, VIVUS, Santarus and Celgene

  

   Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Merck & Co. Inc. (NYSE:MRK), GlaxoSmithKline...

  More news about: Zacks Investment Research, Inc. , Merck & Co. Inc. , GlaxoSmithKline , VIVUS Inc. , Santarus, Inc. , Celgene Corporation

• Apr 16, 2013, 14:30 ET

  VIVUS Announces FDA Approval of Qsymia REMS Modification Allowing Access Through Certified Retail Pharmacies

   VIVUS, Inc. (Nasdaq: VVUS) today announced that the U.S. Food and Drug Administration (FDA) has approved its amendment and modification to the Risk Evaluation and Mitigation Strategy (REMS) for Qsymia® (phentermine and topiramate extended-release) capsules CIV. The amendment, submitted...

  More news about: VIVUS, Inc.

• Apr 10, 2013, 07:00 ET

  New Obesity Education Program To Premiere At American College of Physicians (ACP) Annual Meeting

  A new educational program, Excess Weight and Your Health: A Guide to Effective, Healthy Weight Loss, developed by the Obesity Action Coalition (OAC) and the American College of Physicians (ACP), will be released today at Internal Medicine 2013, the annual scientific meeting of the ACP. The booklet...

  More news about: VIVUS, Inc. , American College of Physicians (ACP) , Internal Medicine 2013 , Obesity Action Coalition (OAC)

• Mar 25, 2013, 06:00 ET

  Analysis In Health Economics Review Concludes Effective Medical Obesity Treatment Could Reduce Medicare Spending

   VIVUS, Inc. (Nasdaq:  VVUS) announced today that a new study demonstrates that effective medical treatment providing 10% to 15% weight loss could lead to significant improvements in Medicare spending by reversing or reducing significant health consequences such as type 2 diabetes,...

  More news about: VIVUS, Inc.